Literature DB >> 26037386

Influence of chronic illnesses and underlying risk conditions on the incidence of pneumococcal pneumonia in older adults.

Angel Vila-Corcoles1, Carlos Aguirre-Chavarria1, Olga Ochoa-Gondar2, Cinta de Diego1, Teresa Rodriguez-Blanco3, Frederic Gomez4, Xavier Raga5, Luis Barnes5, Ramon Magarolas4, Leonardo Esteban4.   

Abstract

OBJECTIVE: To investigate hospitalizations from pneumococcal pneumonia in older adults with specific underlying chronic conditions, evaluating the influence of these conditions in developing pneumonia.
METHODS: Population-based cohort study involving 27,204 individuals ≥ 60 years old in Southern Catalonia, Spain. All cases of hospitalization from pneumococcal pneumonia (bacteremic and nonbacteremic) were collected since 01/12/2008 until 30/11/2011. Cox regression was used to calculate hazards ratio (HR) and estimate the association between baseline conditions and the risk of developing pneumococcal pneumonia.
RESULTS: Maximum incidences (per 1000 person-years) appeared among patients with history of prior pneumonia (14.6), nursing home residents (12.8), persons with immunodeficiency/asplenia (7.7) and patients with chronic pulmonary disease (7.6). In multivariable analysis, age (HR: 1.05), nursing home residence (HR: 4.59), history of prior pneumonia (HR: 3.58), stroke (HR: 2.50), chronic heart disease (HR: 1.53), chronic pulmonary disease (HR: 4.09), diabetes mellitus (HR: 1.66), smoking (HR: 1.69) and immunosuppressive medication (HR: 1.87) appeared significantly associated with an increased risk of pneumococcal pneumonia.
CONCLUSION: Our data support that nursing home residence, chronic pulmonary disease and immunocompromising conditions are the underlying conditions most strongly associated with an increasing risk of pneumococcal pneumonia in older adults. This data underline the need for better prevention strategies among these persons.

Entities:  

Keywords:  Incidence; Pneumococcal pneumonia; Risk factors; Streptococcus pneumoniae

Mesh:

Year:  2015        PMID: 26037386     DOI: 10.1007/s15010-015-0801-y

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  25 in total

1.  Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era.

Authors:  K A Robinson; W Baughman; G Rothrock; N L Barrett; M Pass; C Lexau; B Damaske; K Stefonek; B Barnes; J Patterson; E R Zell; A Schuchat; C G Whitney
Journal:  JAMA       Date:  2001-04-04       Impact factor: 56.272

2.  Invasive pneumococcal infection in Baltimore, Md: implications for immunization policy.

Authors:  L H Harrison; D M Dwyer; L Billmann; M S Kolczak; A Schuchat
Journal:  Arch Intern Med       Date:  2000-01-10

3.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

4.  Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination.

Authors:  M S Dworkin; J W Ward; D L Hanson; J L Jones; J E Kaplan
Journal:  Clin Infect Dis       Date:  2001-02-28       Impact factor: 9.079

Review 5.  The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known.

Authors:  D S Fedson; J A Scott; G Scott
Journal:  Vaccine       Date:  1999-07-30       Impact factor: 3.641

6.  Risk factors and pathogenic significance of bacteremic pneumonia in adult patients with community-acquired pneumococcal pneumonia.

Authors:  Cheol-In Kang; Jae-Hoon Song; So Hyun Kim; Doo Ryeon Chung; Kyong Ran Peck; Visanu Thamlikitkul; Hui Wang; Thomas Man-kit So; Po-Ren Hsueh; Rohani Md Yasin; Celia C Carlos; Pham Hung Van; Jennifer Perera
Journal:  J Infect       Date:  2012-08-23       Impact factor: 6.072

7.  Increased risk of pneumococcal infections in cardiac transplant recipients.

Authors:  I J Amber; E M Gilbert; G Schiffman; J A Jacobson
Journal:  Transplantation       Date:  1990-01       Impact factor: 4.939

8.  Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study.

Authors:  Olga Ochoa-Gondar; Angel Vila-Corcoles; Teresa Rodriguez-Blanco; Frederic Gomez-Bertomeu; Enric Figuerola-Massana; Xavier Raga-Luria; Imma Hospital-Guardiola
Journal:  Clin Infect Dis       Date:  2014-02-13       Impact factor: 9.079

9.  Rationale and design of the CAPAMIS study: effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke.

Authors:  Angel Vila-Corcoles; Inmaculada Hospital-Guardiola; Olga Ochoa-Gondar; Cinta de Diego; Elisabet Salsench; Xavier Raga; Cruz M Fuentes-Bellido
Journal:  BMC Public Health       Date:  2010-01-19       Impact factor: 3.295

Review 10.  Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques.

Authors:  Maria A Said; Hope L Johnson; Bareng A S Nonyane; Maria Deloria-Knoll; Katherine L O'Brien; Felipe Andreo; Bojana Beovic; Silvia Blanco; Wim G Boersma; David R Boulware; Jay C Butler; Jordi Carratalà; Feng-Yee Chang; Patrick G P Charles; Alejandro A Diaz; Jose Domínguez; Naomi Ehara; Henrik Endeman; Vicenç Falcó; Miquel Falguera; Kiyoyasu Fukushima; Carolina Garcia-Vidal; Daniel Genne; Igor A Guchev; Felix Gutierrez; Susanne S Hernes; Andy I M Hoepelman; Ulla Hohenthal; Niclas Johansson; Vitezslav Kolek; Roman S Kozlov; Tsai-Ling Lauderdale; Ivana Mareković; Mar Masiá; Matta A Matta; Òscar Miró; David R Murdoch; Eric Nuermberger; Richard Paolini; Rafael Perelló; Dominic Snijders; Vanda Plečko; Roger Sordé; Kristoffer Strålin; Menno M van der Eerden; Angel Vila-Corcoles; James P Watt
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

View more
  6 in total

1.  Cigarette smoke exposure worsens acute lung injury in antibiotic-treated bacterial pneumonia in mice.

Authors:  Jeffrey E Gotts; Lauren Chun; Jason Abbott; Xiaohui Fang; Naoki Takasaka; Stephen L Nishimura; Matthew L Springer; Suzaynn F Schick; Carolyn S Calfee; Michael A Matthay
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-03-15       Impact factor: 5.464

2.  Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects.

Authors:  Karen Ciprero; Kirill A Zykov; Nikolay I Briko; Tulin Shekar; Tina M Sterling; Elizaveta Bitieva; Jon E Stek; Luwy Musey
Journal:  Hum Vaccin Immunother       Date:  2016-05-05       Impact factor: 3.452

3.  Burden of pneumococcal disease among adults in Southern Europe (Spain, Portugal, Italy, and Greece): a systematic review and meta-analysis.

Authors:  Adoración Navarro-Torné; Eva Agostina Montuori; Vasiliki Kossyvaki; Cristina Méndez
Journal:  Hum Vaccin Immunother       Date:  2021-06-09       Impact factor: 4.526

4.  Prevalence of high, medium and low-risk medical conditions for pneumococcal vaccination in Catalonian middle-aged and older adults: a population-based study.

Authors:  O Ochoa-Gondar; I Hospital; A Vila-Corcoles; M Aragon; M Jariod; C de Diego; E Satue
Journal:  BMC Public Health       Date:  2017-06-29       Impact factor: 3.295

5.  Increased incidence of adult pneumococcal pneumonia during school holiday periods.

Authors:  Priya Daniel; Chamira Rodrigo; Thomas Bewick; Carmen Sheppard; Sonia Greenwood; Tricia M McKeever; Mary Slack; Wei Shen Lim
Journal:  ERJ Open Res       Date:  2017-03-14

6.  Mortality and costs of pneumococcal pneumonia in adults: a cross-sectional study.

Authors:  Lessandra Michelin; Fernanda M Weber; Bruna W Scolari; Bruna K Menezes; Maria Carolina Gullo
Journal:  J Bras Pneumol       Date:  2019-10-17       Impact factor: 2.624

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.